about
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL: one-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.The vasopressin system: new insights for patients with kidney diseases: Epidemiological evidence and therapeutic perspectives.A Fully Automated Web-Based Program Improves Lifestyle Habits and HbA1c in Patients With Type 2 Diabetes and Abdominal Obesity: Randomized Trial of Patient E-Coaching Nutritional Support (The ANODE Study).Non-severe hypoglycemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial.Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I StudyPrognostic Values of Inflammatory and Redox Status Biomarkers on the Risk of Major Lower-Extremity Artery Disease in Individuals With Type 2 DiabetesA Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR StudyClinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort studyPlasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 DiabetesMore Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT TrialPlasma Apelin and Risk of Type 2 Diabetes in a Cohort From the CommunityChronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI ProgramLeukocyte Telomere Length, DNA Oxidation, and Risk of Lower-Extremity Amputation in Patients With Long-standing Type 1 DiabetesPhenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO studyDiabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters
P50
Q38597991-FA53CA98-5535-4817-B36A-7949B8013985Q39361569-A5E564B2-B00E-4D3A-B04C-8C7AFB198265Q41998074-9CD107D7-8C38-476C-A702-9A1A8BE2CAA1Q47161381-1DAA59D4-A5C1-49A5-9C64-8357E8F90CC6Q47173134-0F8B5D06-3BE3-40EA-92AA-B904C0272568Q47684311-71A5FE93-2A76-4333-8512-4B019A959AEFQ58612828-63DB2559-801C-4D23-AA93-CF0ECDF2C7CFQ59315334-4423030F-05AE-4091-9DA5-9E5D7ECBA543Q89080788-DF6DD8E2-3CC9-4095-A7AF-4335C4AD9FEBQ89230569-B72A5492-364B-454A-BAA6-660313925220Q90465947-2151ABE1-97D6-4365-8111-C72577C9C392Q90926497-0D35D11E-9F34-4DD3-8EB1-6F703148C91DQ91734221-6F8D074D-641B-4C02-9055-885C1CBB757BQ92888233-58ABA6C4-8B95-438F-87B4-932E4E1BBDBBQ92976406-1F1664AD-14F6-425F-83F7-BB93773E4567Q96023320-456901FE-C62B-419D-9F28-0EB4ECBE64ECQ96431322-4AC5060D-9A2B-4670-8F49-ACC6FF6C3B70
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ronan Roussel
@ast
Ronan Roussel
@en
Ronan Roussel
@es
Ronan Roussel
@nl
type
label
Ronan Roussel
@ast
Ronan Roussel
@en
Ronan Roussel
@es
Ronan Roussel
@nl
prefLabel
Ronan Roussel
@ast
Ronan Roussel
@en
Ronan Roussel
@es
Ronan Roussel
@nl
P106
P31
P496
0000-0003-2292-8363